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Abstract 
Autoinflammatory syndromes are a group of disorders characterised by recurring episodes 
of inflammation as a result of specific defects in the innate immune system. Patients with 
autoinflammatory disease present with recurrent outbreaks of chronic systemic inflammation that 
are mediated by innate immune cells, for the most part. A number of these diseases arise from 
defects in the tumour necrosis factor (TNF) receptor signalling pathway leading to elevated levels of 
inflammatory cytokines. Elucidation of the molecular mechanisms of these recently defined 
autoinflammatory diseases has led to a greater understanding of the mechanisms of action of key 
molecules involved in TNFR signalling, particularly those involved in ubiquitination, as found in 
haploinsufficiency of A20 (HA20), otulipenia/otulin-related autoinflammatory syndrome (ORAS) and 
linear ubiquitin chain assembly complex (LUBAC) deficiency. In this review we also address other 
TNFR signalling disorders such as (TNF) receptor ?associated periodic syndrome (TRAPS), RELA 
haploinsufficiency, RIPK1-associated immunodeficiency and autoinflammation, X-linked ectodermal 
dysplasia and immunodeficiency (X-EDA-ID) and we review the most recent advances surrounding 
these diseases and therapeutic approaches currently used to target these diseases. Finally, we 
explore therapeutic advances in TNF-related immune based therapies and explore new approaches 
to target disease-specific modulation of autoinflammatory diseases. 
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Introduction: molecular control of TNFR1-mediated signalling 
TNFR Signalling 
TNF is a potent inflammatory cytokine which signals via two distinct receptors, TNF receptor 
1 (TNFR1) and TNFR2, and mediates a number of physiological functions essential for immune 
regulation, cell proliferation, survival and death. TNF is expressed as a trimeric type II 
transmembrane protein (mTNF) which can be cleaved by TNF-converting enzyme (TACE, or 
ADAM17) to give rise to a soluble extracellular TNF (sTNF) (1,2). Both mTNF and sTNF exert their 
physiological functions by binding to either TNFR1 or TNFR2, on target cells. Following activation by 
TNF, TNFR1 recruits both receptor-interacting serine/threonine protein kinase 1 (RIPK1) and TNF-
receptor-associated death domain (TRADD) to the cytoplasmic death domain (DD) of the receptor 
(3) whereas TNFR2 does not have a death domain and, instead, signals through recruitment of TNFR-
associated factor 2 (TRAF2) protein (4,5). Both TNFR1 and TNFR2 signalling pathways can lead to 
activation of the classical nuclear factor-NB (NF-NB) signalling pathway leading to cell survival and 
cell proliferation, whereas TNFR1 can also lead to the initiation of cell death pathways leading to 
apoptosis or necroptosis, depending on the metabolic state of the cell (6).  
 
Ubiquitination in TNF-signalling 
Post-translational ubiquitination in TNF signalling plays a major role in regulating immune 
cell fate and directs the formation of distinct signalling complexes following activation of TNFR1, 
namely complex I, IIa, IIb and IIc, all of which contain the core proteins TNFR1, TRADD and RIPK1 
(7,8). Ubiquitin (Ub) chains are highly conserved and assembled in response to activation before 
being covalently attached to target proteins via E3 Ub-ligase enzymes, to reinforce protein stability 
and activation or enable protein degradation (For detailed reviews see (9,10)). Ubiquitination is a 
reversible process whereby Ub chains can be hydrolysed by a class of enzymes known as 
deubiquitinases (DUBs) (11). Several DUBs, including A20, OTULIN, cylindromatosis (CYLD) and 
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Cezanne, function as negative regulators of NF-NB signalling (12). Dysregulation in ubiquitin 
proteasome signalling (UPS) has been reported in a number of autoinflammatory disorders, 
including linear ubiquitin chain assembly complex (LUBAC) deficiency (13,14), haploinsufficiency of 
A20 (HA20) (15), and otulipenia/otulin-related autoinflammatory syndrome (ORAS) (15,16) and 
these will be discussed in detail in this review. 
 
TNFR signalling via complex I 
Complex I is composed of TRADD (3), RIPK1 (17), TRAF2/5 (18), cellular inhibitor of apoptosis 
protein 1 (cIAP1) or cIAP2 and LUBAC (19). LUBAC is composed of three proteins, heme-oxidised 
IRP2 ubiquitin ligase 1 (HOIL-1), shank-associated RH domain-interacting protein (SHARPIN) and 
HOIL-1 interacting protein (HOIP) (reviewed in (7)). Initially, cIAP1/2 and TRAF2/5 attach K63-linked 
Ub chains to RIPK1 (20,21) which subsequently leads to LUBAC-mediated attachment of M1-linked 
chains to RIPK1 (19,22). This assembly leads to the recruitment of two signalling complexes, with 
transforming growth factor (TGF)E-activated kinase (TAK) 1 complex (consisting of TAK1 and TAK-
binding protein 2/3 (TAB2/3)) K63-linked chains, and the inhibitor of NB (INB) (IKK) complex 
(consisting of IKKD, IKKE and NF-NB-essential modulator (NEMO)), via M1-linked chains (19,22-24).  
The polyubiquitin chains present on NEMO and RIPK1 are bound by the TAK1 complex; this 
is essential as it phosphorylates and stimulates the catalytic IKKE subunit to phosphorylate and 
degrade /ʃɲ thereby activating NF-NE which, in turn, promotes the transcription of target genes 
required for cell survival and proliferation (20,25,26). The TAK1 complex also phosphorylates 
mitogen-activated kinases (MAPK), p38 MAPK and c-Jun N-terminal kinase (JNK) in a signalling 
cascade which leads to transcription of AP1 target genes (Figure 1) (20,23). The various types and 
concentration of polyubiquitin chains attached to RIPK1 have been shown to modulate the activity 
of recruited proteins which signal via complex I; although RIPK1 attachment to NEMO is 
preferentially mediated by M1-linked chains, NEMO can also bind via K63- and K11-linked chains. 
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This differential offers up several possibilities for fine-tuning ubiquitin dependent signalling 
mediated by TNF and also for IL-1E mediated activation of NF-NB via the IL-1 receptor (IL-1R) (for 
detailed review see (7)).  A recent study shows that ubiquitination also ƌĞŐƵůĂƚĞƐZ/W< ? ?ƐĐǇƚŽƚŽǆŝĐ
potential, not only through activation of the NK-NB pathway but also by directly supressing RIPK1 
kinase activity, via ubiquitin-dependent inactivation (27). 
 
IL-1 Receptor signalling 
NF-NB activation is modulated via a complex cross-talk of several signalling pathways with 
shared components for activating and inhibiting this pathway. The pro-inflammatory cytokine, IL-1E 
(along with IL-1D and IL-1 receptor antagonsist, IL-1Ra) binds to the IL-1R leading to the downstream 
activation of NF-NB (28,29). Following ligand binding, the IL-1R complex leads to the recruitment of 
the E3-ligase TNF receptor associated factor (TRAF6) and the ubiquitin E2 ligase complex which 
conjugates K63-linked chains to interleukin-1 receptor ?activated protein kinase (IRAK1) (30,31). This 
ubiquitination process allows for binding and activation of TAK1 and IKKE through phosphorylation 
in a similar manner to TNFR signalling pathway (32). Interestingly, the DUB, A20 also regulates the 
ubiquitin status of TRAF6 and therefore regulates activation of this pathway (33). 
TNFR signalling via complex IIa, IIb, IIc 
Termination of TNF-induced NF-NB activation requires breakdown of the Ub network of 
complex I. As immune responses must be tightly controlled to avoid chronic inflammation, DUBs are 
present to regulate this process and target cells for regulated apoptosis, where appropriate. For the 
formation of complex IIa, DUBs remove K63 and M1-linked chains from RIPK1 allowing it to 
dissociate from membrane bound complex I and interact with TRADD and FAS-associated death 
domain (FADD) and pro-caspase-8, and the cellular FLICE-like inhibitory protein long (cFLIPL) (34). 
Alternatively, complex IIb formation occurs when RIPK1 is not ubiquitinated due to degradation of 
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cIAPs. As a result, RIPK1 dissociates from complex I to interact with RIPK3, pro-caspase-8 and FLIPL 
(6,35).  
Apoptosis is executed on generation of active caspase-8 by both complex IIa and complex 
IIb. At the same time, deubiquitinated RIPK1 and RIPK3 must be cleaved by pro-caspase-8-FLIPL-
heterodimer or active caspase 8 to prevent cells from undergoing necroptosis (6,35,36). If RIPK1 and 
RIPK3 are not cleaved, they form complex IIc which activates mixed lineage kinase domain-like 
protein (MLKL), and induces necroptosis by disrupting the integrity of the plasma membrane (3,37). 
This, in turn, leads to the release of damage associated molecular patterns (DAMPs), which can lead 
to a prolonged immune response, as may occur with trauma and severe infections (38). 
 
Autoinflammatory diseases with dysregulated TNF signalling 
Aberrant TNFR signalling, through uncontrolled production or function of TNF, has been 
linked to a number of inflammatory diseases, including rheumatoid arthritis (RA), ankylosing 
spondylitis (AS), juvenile idiopathic arthritis (JIA), psoriasis, psoriatic arthritis (PsA) and inflammatory 
bowel disease (IBD). In this review we discuss autoinflammatory diseases which arise from 
mutations in genes encoding components of the TNF signalling pathway. 
 
Tumour Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) 
Tumour necrosis factor (TNF) receptor ?associated periodic syndrome (TRAPS) is a rare 
autosomal dominant multisystem genetic disorder caused by mutations in the TNFRSF1A (tumour 
necrosis factor receptor superfamily member 1A) gene, which encodes TNFR1 (39), which result in 
an autoinflammatory phenotype. Several pathogenic mechanisms operate synergistically in TRAPS 
pathogenesis, including non-canonical unfolded protein response (UPR), mitochondrial reactive 
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oxygen species (mtROS), and impaired autophagy. It is likely that some mechanisms are mutation 
and cell ?type specific, thereby explaining some of the clinical heterogeneity of TRAPS and the 
manifold underlying pathological processes (reviewed in (40)).  
Upregulation of UPR response genes has been reported in TRAPS patients (41), with 
activation of the endoplasmic reticulum (ER)-associated endonuclease, inositol-requiring enzyme 1 
(IRE-1), which is one of the three ER stress sensors, resulting in hyper-responsiveness to 
lipopolysaccharide (LPS) with release of pro-inflammatory cytokines, IL- ?ɴ ? dE& ĂŶĚ />-6. This 
enhanced inflammatory cytokine production is mediated by sustained phosphorylation of JNK and 
p38 MAPK, and maintained by mtROS from dysfunctional mitochondria (42). Furthermore, mtROS 
may inactivate MAPK phosphatases and perpetuate MAPK activation (43) in cells from these 
patients. A number of recent studies have suggested other mechanisms to explain LPS hyper-
responsiveness, whereby activated IRE1, exerts its endonuclease function to target a number of 
mRNA and miR species, thereby constraining protein production and resolving ER stress (44). Two 
miRNA species in particular, miR155 and miR146a, are specific targets of IRE1 and these two miRNA 
species have been identified as regulators of cellular response to LPS (45).  
 Selective therapies targeting the TNF signalling pathway were the first biologics to be used in 
TRAPS. Despite its biological plausibility in a disease involving constitutive TNF signalling the TNF 
blocker, etanercept proved to have limited efficacy in treating these patients. The initial clinical 
response to TNF blockade was followed by gradual loss of clinical efficacy in subsequent months and 
year(s), suggesting that these patients develop tachyphylaxis to anti-TNF therapy by acquiring 
alternative poorly understood pathways of TNFR1 signalling.  
Over the years IL-1 blocking agents have become the preferred therapy in TRAPS with a 
number of case reports of sustained response to anakinra (46). The first results of a trial of 
canakinumab in familial mediterranean fever (FMF), mevalonate kinase deficiency (MKD) and TRAPS 
were reported in 2016 (47) and the follow-up publication was in 2018 (48). The 2018 paper reported 
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that significantly more patients receiving canakinumab had a complete response than the placebo 
group at week 16, and the risk of developing potentially fatal amyloidosis has been substantially 
reduced by the use IL-1 blockade in these patients.  
 
A20 haploinsufficiency (HA20) 
The tumour necrosis factor alpha induced protein 3 (TNFAIP3) gene encodes for the A20 
protein which is a potent anti-inflammatory signalling molecule involved in negative regulation of 
TNF-NF-NB signalling. Genetic ablation of A20 in mice leads to multi-organ inflammation, cachexia, 
and perinatal death (49), whereas cell specific deletions of A20 in B cells/ T cells and/or epithelial 
cells give rise to a spectrum of disease phenotypes which closely resemble human autoimmune 
diseases (50).  
In 2016, Zhou and colleagues described a new autoinflammatory disease caused by 
dominantly inherited loss of function mutations in the TNFAIP3 gene, leading to A20 
haploinsufficiency, designated as HA20 (15). They identified mutations in six unrelated families with 
early-onset systemic inflammation resembling the polygenic disorders, Behçet ?Ɛ disease (BD) and 
systemic lupus erythematosus (SLE). Classically, people with HA20 present with childhood-onset 
episodic fevers, recurrent oral, genital and/or gastrointestinal ulcers, ocular inflammation and 
arthralgia/arthritis (15,51). Since the initial discovery, a number of additional HA20 cases have been 
documented (51-56). The occurrence of an autoimmune phenotype in some patients is not 
surprising given that several autoimmune conditions have been associated with TNFAIP3 gene 
polymorphisms, such as RA, JIA, psoriasis, SLE, IBD, type 1 diabetes (T1D) and coronary artery 
disease (57-64). It is thought that HA20 might synergise with other genetic factors, such as HLA-B27, 
which is a known susceptibility locus PsA, AS and reactive arthritis (65), and also that autoimmunity 
may develop as a complication of HA20, due to increased differentiation of TH17 cells (53). In a 
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recent study, large deletions on chromosome 6 comprising 50 genes, including TNFAIP3, were 
identified in patients with systemic inflammation, psychomotor and growth delay (66) providing 
further support for anti-inflammatory therapy as a treatment option for these patients.  
 A20 is a 790-residue ubiquitin editing enzyme which contains an ovarian tumour (OTU) 
domain in the amino-terminal followed by seven zinc-finger (ZnF) domains (67). The majority of 
HA20-associated mutations are located within the OTU domain, leading to truncated mutant 
proteins of different length domains (15,53,56). Defective removal of K63-linked Ub from the 
adaptor proteins, after stimulation with TNF, was observed in HEK cells expressing mutant A20, and 
this finding has been corroborated in patient-derived cells, whereby defective A20 leads to increased 
ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶŽĨ/<<ɲ ?/<<ɴwith enhanced INɲdegradation alongside increased NF-NB ?mediated 
proinflammatory cytokine release (15). Interestingly, TNF stimulated PBMCs and serum samples of 
patients with active disease have high levels of a range of proinflammatory cytokines, irrespective of 
mutation type and position, suggesting the presence of constitutive activation of both NF-NB and 
NLRP3 inflammasome pathways (15,53,58); in murine models, A20/Tnfaip3 was shown to 
downregulate the NLRP3 inflammasome (68,69).  
This inflammatory state has led to successful treatment of patients with cytokine inhibitors, 
such as anti-TNF (infliximab), anti-IL-1 (anakinra) and anti-IL-6 (tocilizumab), which have all shown 
efficacy in controlling systemic inflammation in patients with HA20 (51). It is likely that a number of 
other HA20 cases will emerge due to revised diagnoses with successful therapeutic interventions, as 
with a patient recently diagnosed with Adult-KŶƐĞƚ ^ƚŝůů ?Ɛ ŝƐĞĂƐĞ  ?AOSD), in whom a novel 
heterozygous variant in TNFAIP3 was found and successfully treated with anti-IL-6 therapy, 
tocilizumab (70).  
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OTULIN (also called gumby), is a highly conserved deubiquitinase enzyme, regulating the 
ubiquitination status of signalling pathway proteins via the hydrolysation of M1-linked Ub chains, 
resulting in specific protein deubiquitination. Novel homoallelic mutations in the FAM105B gene that 
encodes OTULIN were found in three unrelated patients of Pakistani and Turkish origin, and the 
name otulipenia was adopted to indicate a decreased expression of mutant proteins (71). 
Simultaneously, another group described the same Pakistani family and named the disease as otulin-
related autoinflammatory syndrome (ORAS). These patients present with neonatal-onset systemic 
inflammation, joint swellings, prolonged fevers, diarrhoea, sterile neutrophilia, growth deficiency 
and lipodystrophy (16,71). OTULIN regulates inflammatory signals via deubiquitination of M1-linked 
Ub chains formed on LUBAC complex targets, such as NEMO, RIPK1, TNFR1, nucleotide-binding 
oligomerization domain-containing protein 2 (NOD-2) and apoptosis-associated speck-like protein 
containing a CARD (ASC), which regulate of the NF-NB and MAPK pathways (71-73). Similar to HA20, 
disease-associated mutations also reside in the OTU domain of OTULIN and are predicted to affect 
binding of OTULIN to linear Ub chains, thereby preventing the deubiquitination of target substrates. 
Although A20 and OTULIN have roles in attenuating ubiquitination in common signalling 
pathways, patients with otulipenia have a more severe phenotype as a result of two factors; (i) 
otulin has a unique non-redundant function in regulating the linear Ub pathway and (ii) patients 
have a more profound protein deficiency (71). Similar to HA20, patient-derived primary cells 
(monocytes, dendritic and T cells) secrete TNF, IL-6, IL-12, IL-18, IL-1E and IFNJ cytokines upon 
stimulation with LPS, TNF or IL-1E. Infliximab proved to be highly effective in reducing these 
inflammatory markers, as well as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) 
in one patient with OTULIN deficiency; however, neither etanercept or anakinra were effective in 
reducing active disease symptoms (71). Mice models with OTULIN knock out mutations exhibit a 
similar phenotype, with severe TNF-associated inflammation due to overactivation of NF-NB in 
myeloid cells, but also downregulation of the LUBAC complex in lymphoid cells (16). OTULIN has also 
been shown to be a key regulator of the canonical Wnt signalling pathway, thereby playing an 
Otulipenia/OTULIN-related autoinflammatory syndrome (ORAS) 
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important role in craniofacial and neuronal development, as well as angiogenesis (74). A recent 
study proposed that LUBAC activity is promoted by OTULIN, rather than being counteracted, thus 
preventing LUBACs auto-ubiquitination (75). Furthermore, mice that express inactive OTULIN 
present with features associated with deficient LUBAC activity and die at mid-gestation as a result of 
TNFR1-mediated cell death (76).  
 
LUBAC deficiency (HOIP/HOIL) 
 Several autoinflammatory disorders are associated with mutations in various components of 
LUBAC, such as HOIP and HOIL. It was first shown that Hoip
-/- 
mice die during embryogenesis, due to 
aberrant TNFR1 driven cell death; furthermore, mice can be rescued from embryonic lethally by 
ablation of TNFR1 (76). Peltzer et al. demonstrated that HOIL-1 is a fundamental component of 
LUBAC and this subunit is required for healthy embryonic development (77). Hoil-1
-/-
 mice die during 
embryogenesis due disruptions in blood vessels formation. Interestingly, Tnfr1/Hoil-1 double-
knockout (DKO) mice did not prevent embryonic lethality, but just delayed it (77). The authors found 
that only combined loss of caspase-8 with MLKL resulted in viable Hoil-1-deficient mice, elucidating 
the protective role of HOIL-1 in the NF-ʃ signalling pathway (77). 
 HOIL-1 and HOIP deficiencies are recessively inherited diseases caused by mutations in the 
highly conserved PUB domain, resulting in truncated mutants which ultimately destabilise the entire 
LUBAC complex (13,14). Patients with mutations in HOIP or HOIL-1 present with similar clinical 
manifestations of systemic autoinflammation, recurrent infections, muscular amylopectinosis and 
periodic fevers (78). HOIL/HOIP deficient fibroblasts from patients, showed decreased NF-NB 
activation in response to TNF and IL-1E administration; however, ƉĂƚŝĞŶƚƐ ? ŵŽŶŽĐǇƚĞƐ ĚŝƐƉůĂǇĞĚĂ
selective response to IL-1E but not to TNF, suggesting cell-type specificity (13,14). It was also 
recently reported that LUBAC confers a protective role on keratinocytes, and that conditional 
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deletion of Hoip and Hoil-1 results in severe dermatitis and postnatal lethality, mainly induced by 
TNF, TNF-related apoptosis-inducing ligand (TRAIL) and CD95L (79). TNFR1 ablation did not prevent 
the development of dermatitis, but rather delayed it into adulthood, when triggered by RIPK1 
kinase-driven apoptosis (79). In contrast, a naturally occurring mutation that ablates SHARPIN 
expression in the cpdm strain of mice resulted in chronic proliferative dermatitis (80) which can be 
prevented by crossing the mice with Tnf
-/-
 or Tnfr
-/-
 mice, suggesting that this inflammatory condition 
is TNF dependent (81,82). In addition, it appears that complete ablation of SHARPIN in the cpdm 
mice can be rescued when crossed with a mouse expressing kinase-inactive RIPK1 or RIPK3-null mice 
which suggests that SHARPIN and M1-linked polyubiquitination are negative regulators of RIPK1-
dependent necroptosis signalling (7,81).  
These findings suggest a different mechanism by which dermatitis can occur, with potential 
implications for the treatment of autoinflammatory disorders. Although not yet reported in the 
clinic, SHARPIN mutations are likely to represent a similar problem to that encountered in HOIL and 
HOIP deficiencies. LUBAC deficiencies still represent an unexplored territory in the clinical field; 
however, the scientific contributions presented here advance our understanding of 
autoinflammation and the treatment of these rare conditions. Whereas TNF-inhibitory treatment 
only temporarily ameliorated pathology in one HOIL-deficient patient, the benefit to OTULIN-
deficient patients was far more substantial (14). It is possible that TNF inhibition, in combination 
with RIPK1, TRAIL or CD95L inhibitors would be a better therapeutic approach for patients with 
LUBAC deficiencies. 
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The transcription factor p65, also known as RelA, is a NF-NB family member associated with 
NF-NB heterodimer formation, alongside either p50 or p52 subunits, with consequent nuclear 
translocation and activation (83). The RelA subunit is encoded by the RELA gene, also known as p65 
or NFKB3, and the transcriptomic function of RelA is conserved in mammalian cells (84). RelA
-/-
 mice 
die during embryogenesis due to the toxic effects of TNF in hepatic cells (85). Interestingly, RelA
-/-
 
mice can be rescued from embryonic lethality by creating a RelA/TNF DKO mouse, showing the 
importance of RelA subunit in activating anti-apoptotic genes, and the susceptibility of RelA
-/-
 mice 
to the cytotoxic effects of TNF (86). TNF stimulation of RelA
-/- 
mouse macrophages and fibroblasts 
resulted in TNF-related apoptosis, mediated mainly by TNFR1, which was rescued by reintroduction 
of RelA into the system (85).  
Recently, Chou et al. elucidated the importance of biallelic expression of RelA in maintaining 
human mucosal integrity (87). The article reported a paediatric patient who presented at the age of 
3 with periodic episodes of abdominal pain, vomiting, fever, leucocytosis, and elevated inflammatory 
markers, without evidence of infection or autoantibodies (87). At the age of 5 the patient was 
treated with infliximab and methotrexate (MTX), and went into remission for two years; the disease 
flared after the patient gained weight, which resulted in lower infliximab levels (87). Moreover, the 
ƉĂƚŝĞŶƚƐ ? ĨŝďƌŽďůĂƐƚƐ ? ďƵƚ ŶŽƚ ůǇŵƉŚŽĐǇƚĞƐ ? ƐŚŽǁĞĚ ŚŝŐŚĞƌ ůĞǀĞůƐ ŽĨ ĐǇƚŽƚŽǆŝĐŝƚǇ ĂĨƚĞƌ dE&
administration, with low levels of IL-6 and anti-apoptotic proteins, suggesting that RelA 
haploinsufficiency mainly affects stromal cells (87). Finally, the authors elegantly demonstrated that 
RelA
+/- 
mice developed cutaneous ulceration after TNF exposure, and the RelA
+/-
 phenotype was not 
rescued by bone marrow transplantation from a WT mice donor (87). These results indicate that 
RelA haploinsufficiency arises from epithelial and stromal cell intrinsic defects affecting NF-NB 
activation, resulting in ulceration of mucosal barriers due to cytotoxic effects of TNF. It is remarkable 
that this patient went into remission when receiving infliximab, highlighting the protective effects of 
the RelA subunit and the cytotoxic effects of TNF in stromal cells. 
RELA haploinsufficiency 
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RIPK1-associated immunodeficiency and autoinflammation 
RIPK1 kinase activity is a key determinant of whether a cell activates NF-NB signalling or 
initiates cell death signalling pathways, apoptosis and necroptosis (88,89). Necroptosis and RIPK1 
have been implicated in a number of major human neurodegenerative diseases, including 
ůǌŚĞŝŵĞƌ ?Ɛ ĚŝƐĞĂƐĞ ? ĂŵǇŽƚƌŽƉŚŝĐ ůĂƚĞƌĂů ƐĐůĞƌŽƐŝƐ ? WĂƌŬŝŶƐŽŶ ?s disease, and multiple sclerosis (MS) 
(90). Under pathological conditions, upregulation of TNF can sensitise cells in the CNS to necroptosis 
mediated by RIPK1, with necroptosis promoting further neuroinflammation. Necrostatin-1 (Nec-1), 
an inhibitor of necroptosis has been shown to inhibit RIPK1 kinase activity and block complex II 
formation in response to TNF (91). Nec-1 and the improved analogue Nec-1s have been shown to 
effectively inhibit RIPK1 and also modulate necroptosis in various cellular and animal models of 
human disease (92,93). Other RIPK1 inhibitors, including GSK2982772, have been advanced into 
phase IIa clinical trials for the treatment of non-neurological diseases, including psoriasis, RA and 
ulcerative colitis (UC) (90). 
A recent study by Cuchet-Lourenco et al. describes four patients from three unrelated 
families with homozygous loss-of-function mutations in RIPK1 gene. These patients demonstrated 
immune deficiency, gut inflammation with variable onset and severity and also polyarthritis. In 
contrast to RIPK1-deficient mice, which die shortly after birth, these patients survived for 3 to 13 
years, indicating that, in humans, RIPK1 is not essential for survival (94), which is reminiscent of the 
findings that HOIP- and HOIL-1-deficiencies are lethal in mice but not in humans (76).  
In order to assess the function of TNFR1 signalling, patientƐ ? skin fibroblasts were stimulated 
with TNF; both MAPK phosphorylation and pathway activation were impaired, with reduced 
cytokine production and increased phosphorylation of complex IIc necroptosis pathway 
components, RIPK3 and MLKL (94). Consistent with this result, inhibitors of necroptosis prevented 
cell death, while pan-caspase inhibitors of apoptosis had no effect. Interestingly, LPS-stimulated 
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patient monocytes showed reduced production of IL-6, TNF and IL-12, consistent with the fibroblast 
data, but with increased IL-1E levels. IL-1E production was also increased following 
phytohaemagglutinin (PHA) stimulation suggesting IL-1E production by T cells. Functional studies 
showed RIPK1 knockout THP-1
RIPK1-/-
 cells secreted reduced amounts of IL-6 and IL-10 with an 
increased amount of IL-1E which resembled the cytokine response of the patients. Additionally, 
necroptosis of THP-1
RIPK1-/-
 cells was accompanied with release of caspase-1 and IL-1E suggesting 
concomitant NLRP3 inflammasome activation (94). High pro-inflammatory IL-1E and low anti-
inflammatory IL-10 could therefore contribute to the IBD and arthritis in these patients and should 
thus be considered for treatment with IL-1 inhibitors. One of the patients who received a 
haematopoietic stem cell transplant (HSCT) resolved IBD and arthritis and reduced the frequency of 
infection suggesting an immune cell dysfunction rather than any other cell type (94). RIPK1 functions 
as a critical regulator of immunity and inflammation in both mice and humans; however, the 
mechanisms balancing inflammatory and cell death signalling require further investigation for the 
development of better treatments. 
 
X-linked ectodermal dysplasia and immunodeficiency (X-EDA-ID) 
 Mutations in the IKBKG/NEMO gene, encoding NEMO, cause X-linked recessive ectodermal 
dysplasia and immunodeficiency (EDA-ID), which is characterised by abnormal development of 
ectodermal tissues alongside immune deficiency, low antibody levels and natural killer cell 
dysfunction (95). Defects in IKBKG/NEMO cause defective NF-NB activation and impaired pro-
inflammatory responses. Around 20% of individuals with EDA-ID have disorders involving abnormal 
inflammation including IBD and SLE, and while the clinical aspects of immune deficiency are well 
characterised, the inflammatory responses are less clear.  In these patients, enterocolitis is 
prominent and epithelial cell shedding is present (96). In patients who received allogenic bone 
marrow transplants the immunodeficiency was corrected but the colitis remained, and exacerbated 
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in some cases (97-99). This successful immune restoration suggests that different factors may be 
driving the colitis and immunodeficiency in these patients.  
The importance of NEMO in intestinal epithelia barrier function has been demonstrated in 
an epithelium-specific IKBKG-deficient mouse whereby the mice develop spontaneous colitis, despite 
having a normal immune system, which is prevented when TNF production is abolished (100). These 
findings suggest that when the epithelial barrier is disrupted, and the normal innate immune 
response to this exacerbates inflammation and sustains the colitis. This suggests that NF-NB 
signalling in epithelial cells is required to prevent excessive epithelial cell apoptosis and to maintain 
the epithelial barrier to protect against colitis in human subjects (97). TNF blockade would therefore 
be a promising target, as suggested by the case of an 11 year old boy with X-EDA-ID with severe 
colitis, to whom infliximab was administered, with dramatic improvement of symptoms. Following 
one year ?Ɛ infliximab treatment, mucosal inflammation had almost disappeared and the number of T 
cells carrying the reverted gene was also reduced (99).  
 
TNF therapeutic alternatives 
Anti-TNF therapeutics have revolutionised treatment for a number of inflammatory diseases 
with dysregulated TNF levels. At present, 25 drugs which inhibit or modulate the effects of TNF, are 
approved clinically by the Food and Drug Administration (FDA) and European Medicines Agency 
(EMA) for the treatment of RA, AS, psoriasis, PsA, JIA, CD and UC (101). Although many patients 
benefit from treatment with anti-TNF drugs, a number of patients do not respond well to the 
therapy (102) and it is of some concern that prolonged use of anti-TNF biologics has also been 
shown to increase the prevalence of neurological diseases, such as MS, with several reports showing 
increased CNS demyelination as a possible contribution to disease onset (103). Research suggests 
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that early identification in addition to considering clinical, genetic and immuno-pharmacological 
variables are all important in assessing whether a patient responds well to therapy (104).  
Lessons learnt from anti-TNF therapeutics in these approved diseases have helped to inform 
therapeutic strategies to resolve TNFR/TNF signalling defects in the autoinflammatory diseases 
discussed in this review (Figure 1). For example, patients with diagnoses of HA20 and RELA 
haploinsufficiency, respectively, have been successfully treated with a combination of infliximab and 
MTX (51,87). MTX is an immunosuppressive agent which was initially used to improve clinical 
outcomes of patients with IBS and CD who had developed anti-drug antibodies (ADA) when 
administered anti-TNF biologics (infliximab, adalimumab or golimumab) (105,106).  
Anti-TNF therapeutics have advanced significantly since the discovery of infliximab with 
improvements in antibody specificity, as well as the development of nanoantibodies (107), alongside 
the next generation of cheaper anti-dE&ƌĞĂŐĞŶƚƐŬŶŽǁŶĂƐ “ďŝŽƐŝŵŝůĂƌƐ ?(108,109); all of these have 
provided some promising results for the treatment of chronic inflammatory diseases, such as RA and 
UC (110). Selective targeting of TNFR1 or TRNF2 is another therapeutic strategy which is being 
explored for the treatment of RA, as specific targeting of TNFR1 will block pro-inflammatory effects 
while preserving expansion and activation of Tregs and also maintain protective effects of the TNFR2 
signalling (111,112).  
An alternative approach is to target proteins which form part of the intercellular signalling 
pathways of TNFR. Selectively blocking p38 MAPK directly resulted in a poor clinical response with 
toxicity (113,114); however, a recent study explored the use of an 11-mer TNF peptide (TNF70-80) to 
modulate p38 MAPK indirectly. TNF70-80 binds to TNFR1 and signals through TRAF2 and p38 MAPK, 
which in turn primes neutrophils to initiate a respiratory burst (115). Mukaro et al. generated 
peptides from the TNFR1 sequence which blocked the binding of TNF70-80 and prevented p38 
MAPK activation and subsequent inflammatory response in models of immunity and infection. 
Interestingly, the TNFR peptide does not prevent the binding of TNF to TNFR1 and other signalling 
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molecules it normally activates, but, instead, selectively inhibits p38 MAPK activation and function 
(115). By improving drug targeting, in this way, the rate of potential side-effects of other anti-TNF 
biologics will decrease, but specificity will increase and this will also serve as a valuable tool for 
elucidating mechanisms of disease pathogenesis in vivo.  
An interesting investigative approach has been developed for TRAPS, whereby new 
technologies, ƐƵĐŚĂƐ ‘ƌĞǀĞƌƐĞ-ƉŚĂƐĞ ?ƉƌŽƚĞŝŶŵŝĐƌŽĂƌƌĂǇ ?ZWW), can be used to detect and quantify 
intracellular signalling molecules associated with a particular disease phenotype (116). Using cell line 
models depicting TRAPS, as well as PBMC lysates from C33Y-TRAPS patients relative to controls, the 
RPPA approach was combined with the screening of existing pharmacologically active compounds to 
identify key compounds which modulate the TRAPS signalome. The fluoroquinolone antibiotic, 
lomefloxacin, as well as others from the same class of compounds was found to have the most 
significant effects on pro-inflammatory pathways in TRAPS (116). This approach would be useful for 
other autoinflammatory diseases to identify cellular pathways in the disease state as well as 
candidates for drug repurposing. 
 
Conclusions 
The discovery of autoinflammatory diseases, such as LUBAC deficiency and HA20, has aided 
our understanding of the regulatory components of TNF signalling, and, in particular, highlighted the 
importance of ubiquitination in modulating RIPK1-mediated cell death. Current drugs are not 
disease specific, and aim to target the secondary mediators of inflammation rather than the primary 
processes that drive disease. This can lead to unexpected outcomes, as observed with TRAPS, 
whereby anti-TNF biologics resulted in a dramatic initial response, but with gradual loss of clinical 
efficacy over time in a number of patients. In this situation, epigenetics may play a role in disease 
modulation during biologics-mediated TNF blockade in these patients, a phenomenon which is yet to 
be explored. Although our understanding of TNFR signalling has dramatically improved over the last 
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decade, developing disease specific therapeutics for the rarer autoinflammatory conditions will be 
challenging. 
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Figure Legend 
Figure 1: TNFR signalling defects, autoinflammatory diseases and therapeutics. TNF binding to 
TNFR1 leads to the recruitment of complex I (composed of TRADD, TRAF2/5, cIAP1/2 and RIPK1). 
cIAP1/2 and LUBAC complex add K63-Ub and M1-Ub chains respectively onto RIPK1. K63-Ub chains 
on RIPK1 recruit TAK1 complex (composed of TAK1, TAB2/3), and the M1-Ub chains recruit IKK 
ĐŽŵƉůĞǆ ?ĐŽŵƉŽƐĞĚŽĨEDK ?/<<ɲ ?ɴ ? ?d< ?ĐŽŵƉůĞǆƉŚŽƐƉŚŽƌǇůĂƚĞƐƉ ? ?DW<ĂŶĚ:E<ĂŶĚ/<<ɴ
leading to the translocation of transcription factors, AP1 and NF-kB into the nucleus. A20, CLYD and 
OUTLIN negatively regulate NF-kB signalling to avoid chronic inflammation, by cleaving K63-Ub and 
M1-Ub chains from RIPK1 and the IKK complex and target cells for regulated apoptosis via complex 
IIa. Autoinflammatory diseases detailed in this review are a result of defects in different components 
of the TNFR signalling pathway. TRAPS mutations result in upregulated UPR leading to sustained 
MAPK phosphorylation and cytokine secretion. Treatment consists of anti-TNF or anti-IL-1; but 
recent investigations propose the antibiotic, lomefloxacin, as a potential alternative therapy. RIPK1 
deficiency results in reduced cytokine production but with increased necroptosis. Treatments 
include necroptosis and RIPK1 inhibitors, with suggestions that IL-1 inhibitors could be beneficial. 
Decreased expression of A20 (HA20) or OTULIN (ORAS) lead to activation of NF-kB pathway. 
Treatments include anti-TNF therapies, for ORAS, and both anti-TNF and anti-IL-1 for HA20. LUBAC 
deficiency is due to mutations in LUBAC components, HOIP/HOIL/SHARPIN lead to reduced K63-Ub, 
decreased NF-kB activation and increased RIPK1-mediated apoptosis which is currently treated with 
anti-TNF, but RIPK1 inhibitors could also be of benefit. X-EDA-ID and RELA haploinsufficiency both 
lead to defective NF- kB activation and are both treated with anti-TNF therapies. 
Anti-TNF: Infliximab, Etanercept; Anti-IL-1: anakinra, canakinumab; Anti-IL-6: tocilizumab 
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